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The HIV-pandemic threatens health and life in sub-Saharan Africa, 
with current prevention methods unable to stem the tide of new 
adult HIV-infections.1 Linked to the adult epiemic is the childhood 
epidemic, with mother-to-child transmission (MTCT) one of the 
main modes of transmission. Nearly a third of all children are born 
to HIV-infected women in high-prevalence areas, such as South 
Africa, which has major implications for improved child survival.2 
Contrasting with the adult epidemic, the childhood epidemic can be 
effectively reduced through prevention-of-mother-to-child (PMTCT) 
interventions, decreasing the risk of transmission from 35% to below 
5%.3 Low- and middle-income countries have faced operational 
challenges in offering PMTCT services to all at-risk mother-infant 
pairs but, in South Africa, a new PMTCT era is dawning, with 
intensified PMTCT guidelines released in 2010.4,5
As HIV disease progression in children is rapid, its impact on 
childhood morbidity and mortality will only be decreased if HIV-
infected children are diagnosed early and antiretroviral therapy 
(ART) initiated in infancy.6,7 South Africa released national HIV 
treatment guidelines in 2004, opening ART access to public sector 
patients.8 Diagnosis of HIV infection in adults and children >18 
months old is by HIV ELISA or rapid tests, verifying a positive 
screening test with a confirmatory test. In children <18 months old, 
persistence of maternal HIV antibodies means diagnosis relies on 
virological assays, with HIV DNA PCR (polymerase chain reaction) 
testing most commonly used.8 Sensitivity and specificity of a single 
HIV DNA PCR test is excellent at 98.8% and 99.4% within a research 
environment in Johannesburg.9 Diagnostic services must be available 
for children to access care, and HIV DNA PCR testing is much more 
costly and less widely available than HIV ELISA/rapid testing.10 
With PMTCT programme expansion, infant HIV testing has shifted 
to primary health care facilities using the dry blood spot (DBS) 
technique, aiming at testing all HIV-exposed infants at 6 weeks of 
age.11,12 The SA PMTCT guidelines (2010) recommend that a positive 
HIV DNA PCR test is confirmed by HIV RNA viral load testing.4
To predict the probability of actual disease, clinicians rely on the 
sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) of diagnostic tests. The sensitivity of any test 
is the proportion of people with a positive test among those who 
have the disease, while specificity is the proportion of people with 
a negative test among those without the disease. The PPV is the 
proportion of people with disease among all those with a positive test, 
and the NPV is the proportion of people without the disease among 
those with a negative test result. Both the PPV and NPV depend on 
the prevalence of the disease in the tested population. The predictive 
value is the key characteristic, as it gives information about how likely 
it is that the test result correlates with actual disease.13
We examined our experience of referrals of children incorrectly 
diagnosed as HIV-positive to illustrate the potential implications 
in a changing epidemic within the context of PMTCT programme 
expansion, decreasing HIV transmission rates and an emphasis on 
initiating ART in early infancy before children are symptomatic.
Patients and methods
The Kalafong regional hospital serves an urban population in 
Gauteng Province, and delivers ART care to public sector patients. 
In this retrospective analysis, we included all records of children 
<18 months old referred to the hospital’s HIV clinic between April 
2004 and March 2010, which is the period from the start of the 
national ART programme to the implementation of the updated 2010 
guidelines. The only records excluded were of those initiated on ART 
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Aim. To examine false-positive HIV DNA polymerase chain reaction 
(PCR) test results in children, and the potential implications for the 
paediatric HIV epidemic in sub-Saharan Africa.
Methods. A review was done of records over a 6-year period 
of children less than 18 months old at an HIV treatment site in 
South Africa, to evaluate those with an initial ‘false’-positive HIV 
DNA PCR result, but later proven to be HIV-uninfected with HIV 
DNA PCR and/or quantitative HIV RNA PCR tests. We calculated 
the influence of changing HIV transmission rates on predictive 
values (PV) of HIV DNA PCR tests in a hypothetical population 
of all HIV-exposed infants over a 1-year period. (Positive PV: 
proportion of individuals with a positive test with disease; negative 
PV: proportion of individuals with negative test and no disease).
Results. Of 718 children, 40 with an initial positive HIV DNA 
PCR test were subsequently proven to be HIV-uninfected, resulting 
in a positive PV of 94.4%. Most (75%) uninfected children 
had PMTCT interventions and were asymptomatic or mildly 
symptomatic (77.5%). Calculations using a test specificity of 99.4%, 
as reported previously, show a decrease in positive PV using a 
single-test strategy from 98.6% at 30% HIV transmission rate, to 
94.8% at 10% transmission, to 62.5% at 1% transmission. Reduction 
in test specificity further decreases positive PV at low transmission 
rates.
Conclusion. Decreasing mother-to-child HIV transmission rates 
reduce the positive predictive value of a single HIV DNA PCR test 
result, necessitating adaptations to diagnostic algorithms to avoid 
misdiagnosis and inappropriate treatment, especially with early 
initiation of antiretroviral therapy in asymptomatic infants.
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before referral to Kalafong. The Ethics Review Committee, Faculty of 
Health Sciences, University of Pretoria, approved the study protocol. 
The patient records of all the discharged children after an initial 
false-positive HIV DNA PCR test were reviewed by a paediatrician 
with extensive experience in HIV care. Efforts were made to trace the 
children who were discharged as HIV-uninfected.
The samples for the initial HIV DNA PCR tests were taken either 
at the Kalafong PMTCT follow-up clinic or at regional primary 
health care clinics. One virology laboratory of the National Health 
Laboratory Service (NHLS), linked to a tertiary training hospital, 
processed all HIV DNA PCR tests, using the AMPLICOR HIV-1 
DNA Test, version 1.5 (Roche Molecular Systems, Inc.) from 2004 
until 2009, and the Cobas AmpliPrep/Cobas TaqMan HIV-1 Qual 
test (Roche Molecular Systems, Inc.) thereafter. Standard practice 
in the clinic was to do a confirmatory HIV DNA PCR test and/
or quantitative HIV RNA PCR (‘viral load’) on all newly referred 
children <18 months. Additional HIV-testing in children with an 
initial positive HIV DNA PCR result (‘false positive HIV DNA PCR 
test’) was prompted by either a negative confirmatory HIV DNA 
PCR test or the HIV viral load (quantitative HIV RNA PCR) result 
being undetectable. Further testing depended on the child’s age and 
included additional HIV DNA PCR and viral load tests in children 
<18 months, and HIV ELISA testing in children ≥18 months. The 
decision to discharge the child as HIV-negative was made by the 
treating clinician. Children who at discharge, owing to their young 
age, had not yet had an HIV ELISA test done, were referred to 
primary health care for HIV rapid or ELISA testing at 18 months.
Using estimates of the number of HIV-exposed infants born in 
South Africa during a one-year period, calculations examined the 
influence of changing HIV transmission rates on the PPV and NPV 
of a single HIV DNA PCR test. The literature provided data regarding 
the number of HIV-exposed infants born in South Africa within a 
one-year period and the sensitivity and specificity of the HIV DNA 
PCR test commonly used within the local context.
Results
In 40 of the 718 children aged <18 months at the first Kalafong clinic 
visit, the initial positive HIV DNA PCR test was not confirmed by a 
second HIV DNA PCR (N=12) or HIV RNA PCR test (N=20) or both 
tests (DNA and RNA PCR) (N=8). The median age of all patients at 
first clinic visit was 7 months (range 26 days to 17 months), while 
the median age of those with initial positive HIV DNA PCR results, 
not confirmed subsequently (‘false positive’), was 4 months (range 
1 month - 35 months; one child aged 35 months was referred late 
owing to lost-to-follow-up after initial positive HIV DNA PCR result 
in infancy). The ratio of male and female infants referred to the 
clinic was 1.08 to 1 but, for those with false-positive results, males 
predominated (ratio 2.08:1) (p=0.04).
At HIV re-testing, 15 (37.5%) children subsequently had 2 negative 
virological tests, and 10 (25%) had ≥3 negative virological assays, 
which included combinations of negative HIV DNA PCR and 
undetectable viral load results. Another 15 (37.5%) were discharged 
after at least 1 negative HIV ELISA test in addition to ≥1 negative 
HIV virological assays (negative HIV DNA PCR test or undetectable 
HIV viral load).
Review of the medical records indicated no discharge to have 
been inappropriate, and none of the discharged children was later 
referred back to the clinic as HIV-infected. Telephonic follow-up was 
conducted in August 2010, and none of the 22 (55%) children who 
were traceable had subsequently been diagnosed as HIV-infected.
As part of the confirmatory testing, 49 HIV viral loads were done 
on venous blood on 33 of the HIV-uninfected children, of which 40 
(82%) were undetectable, while 8 in total had 9 detectable viral load 
results: 6 (12%) were between log10 2 and 3, and 3 (6%) were between 
log10 3 and 4, with none above log104 (10 000 copies). The median 
age at initial positive HIV DNA PCR test for this subgroup was 1.5 
months (range 11 days - 9 months), while the median age of the 
detectable HIV viral load was 10 months (range 1 - 46 months). Five 
of the 8 children with detectable viral loads, including the one child 
with low detectable viral loads on 2 occasions, were subsequently 
HIV ELISA non-reactive, while the other 3 children, all discharged 
before age 18 months, had 2 subsequent negative virological assays to 
exclude HIV infection.
Of the uninfected children, 30 (75%) had recorded PMTCT 
interventions, while 5 (12.5%) had no PMTCT interventions, and 
another 5 (12.5%) had no information recorded. Twenty (67%) 
mother-infant pairs had received single-dose nevirapine (NVP), 7 
(23%) had mothers on triple ART with subsequent infant NVP, 2 
(7%) had combined zidovudine (AZT) and NVP interventions, and 1 
(3%) had other PMTCT interventions. Twenty-eight (70%) mothers 
never breastfed their infants, 5 (12.5%) had a breastfeeding history, 
while in 7 (17.5%) this information was not recorded or not known. 
According to WHO HIV clinical staging done at the HIV clinic, 31 
(77.5%) were asymptomatic or had a minor illness (stage 1 and 2), 7 
(17.5%) were classified as symptomatic (with stage 3 or 4 disease), 
and 2 (5%) had not been staged.
In summary: with 40 (out of 718) unconfirmed positive HIV DNA 
PCR tests and 678 (out of 718) confirmed positive tests, the PPV of 
the HIV DNA PCR test in the clinical setting at Kalafong Hospital 
in infants <18 months was calculated at 94.4%. Reasons for these 
false-positive results can arise from specimen problems or inherent 
laboratory assay performance, which was not possible to investigate 
retrospectively, and we therefore continued to examine the relevance 
of these local results within the wider South African context with a 
changing HIV epidemic in children.
Examination of the results in the wider South African 
context
South Africa has a rapidly changing paediatric HIV epidemic, with 
decreasing transmission rates as a result of intensified PMTCT 
interventions. The national HIV prevalence among SA pregnant 
women in 2008 was 29.3% (95% confidence interval (CI) 28.5 - 
30.1%),2 and with a total of 1 069 300 live births14 this means that an 
estimated 313 305 HIV-exposed children were born during that year.
The sensitivity and specificity of a single HIV DNA PCR test 
in a research setting in South Africa is respectively 98.8% and 
99.4%.9 We used this sensitivity and specificity to estimate the 
number of infants testing HIV DNA PCR positive and negative 
with varying HIV transmission rates. Table I shows that the number 
of positive results that are false-positives increases as the HIV 
transmission rate decreases. The PPV remains relatively high when 
the transmission rate is >10%, but drops substantially once the 
transmission rate is <10%. Conversely the number of false-negative 
results decreases as the transmission rate decreases, but the NPV 
remains very high at all transmission rates, approaching 100% with 
very low transmission rates.
Fig. 1 demonstrates the effect on PPV if the specificity of the test 
were to be less accurate when used in clinical setting than the 99.4% 
found in the research environment. When the transmission rate is 
high, the PPV remains high at all levels of specificity; but once the 
transmission rate decreases, PPV decreases markedly with even a 
minor decrease in the specificity of the test by one or two percentage 
points. A similar decrease in the test sensitivity only marginally 
affects the NPV.
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Applying the PPV of 94.4% found in the Kalafong cohort, Fig. 1 
shows that this would correspond to a test specificity of 99.4% and a 
transmission rate of between 8% and 9%, which correlates with the 
clinical experience in the PMTCT follow-up services at the hospital 
(data not shown). This conclusion suggests that the test specificity as 
performed in the clinic is probably holding up to the standards set in 
the research environment.
Discussion
ART has transformed paediatric HIV disease into a treatable condition.1 
Early disease detection and access to ART are priorities to reduce 
childhood morbidity and mortality in sub-Saharan Africa, especially in 
children <1 year old, with survival benefits even when asymptomatic.7 
But placing children on ART commits them to lifelong treatment, 
emphasising the need for an accurate diagnosis before ART initiation.
The HIV DNA PCR test has an excellent sensitivity and specificity 
within a research setting in South Africa, where much attention 
is given to having and training adequate staff. 9 Stretched human 
resources may compromise test sensitivity and specificity in everyday 
clinical use, with greater risk of specimen handling errors at clinic 
and laboratory level. There is also the risk of laboratory errors 
through specimen contamination and inadequate quality control, as 
illustrated by our patients with a false-positive viral load and negative 
confirmatory diagnostic tests.9,11,15
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Table I. Hypothetical HIV DNA PCR results with predictive values in South African HIV-exposed infants in relation to different 
HIV transmission rates (% MTCT)*
HIV transmission rate (% MTCT)
30% 25% 20% 15% 10% 5% 3% 1%
Estimated absolute numbers of HIV-exposed children tested using a single HIV DNA PCR
Number of true-positive HIV DNA 
PCR tests 92 863 77 386 61 909 46 432 30 954 15 477 9 286 3 095
Number of false-positive HIV DNA 
PCR tests 1 316 1 410 1 504 1 598 1 692 1 786 1 824 1 861
Number of true-negative HIV DNA 
PCR tests 217 998 233 569 249 140 264 711 280 283 295 854 302 082 308 311
Number of false-negative HIV DNA 
PCR tests 1 128 940 752 564 376 188 113 38
Predictive values of a single HIV DNA PCR test result
% false-positive HIV DNA PCR tests 1.4% 1.8% 2.4% 3.3% 5.2% 10.3% 16.4% 37.6%
Positive predictive value (PPV) 98.6% 98.2% 97.6% 96.7% 94.8% 89.7% 83.6% 62.4%
% false-negative HIV DNA PCR tests 0.5% 0.4% 0.3% 0.2% 0.1% 0.1% 0% 0%
Negative predictive value (NPV) 99.5% 99.6% 99.7% 99.8% 99.9% 99.9% 100% 100%
*Calculations used HIV DNA PCR test sensitivity of 98.8% and specificity of 99.4% and population data for the year 2008 with an estimated total of 313 305 HIV-exposed infants born 
during the year.
Fig. 1. Positive predictive value (PPV) of the HIV DNA PCR test at varying test specificities and declining HIV transmission rates.
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Our intention was to study how well the HIV DNA PCR test 
performs in an everyday clinical setting within a large-scale HIV 
programme. The PPV of the HIV DNA PCR test for children referred 
to the Kalafong HIV services was 94.4%, which means that 1 in every 
18 children <18 months old referred as HIV-infected on the basis of 
1 positive HIV DNA PCR test result was subsequently determined 
to be HIV-uninfected, either because of sample misallocation or 
inherent viral assay performance. The statistically significant gender 
distribution of more boys than girls having a false-positive HIV DNA 
PCR test is unexplained.
Although the audit spans a 6-year period in which the PMTCT 
interventions were not static but expanding, 75% of children in the 
HIV-uninfected group had access to PMTCT interventions, thereby 
greatly reducing their actual risk of being HIV-infected. Most (77.5%) 
children with false-positive HIV DNA PCR tests were asymptomatic 
or only had minor health problems, and only 12.5% were breastfed, 
with a risk of late postnatal HIV transmission.
This study’s main limitation is that it is a clinic-based retrospective 
audit. Clinicians might not have identified all children misdiagnosed 
as being HIV-infected. Reviewing the medical records indicated that 
none of the discharges as HIV-uninfected was inappropriate. We 
do not have access to all results of follow-up testing, but all of those 
known to have had follow-up testing were confirmed uninfected, and 
none was subsequently referred back to the Kalafong ART site with 
HIV-disease.
The study spans the time from the first availability of ART in 
2004 for children accessing healthcare in the SA public sector up to 
implementation of the updated guidelines in 2010. One major change to 
the guidelines is the immediate start of ART for all children diagnosed 
with HIV before age one year, even if asymptomatic. Their diagnosis of 
HIV infection then relies solely on positive laboratory testing.16
The expanding PMTCT programme has the potential to rapidly 
shift the epidemiology of HIV disease in children, uncoupling it 
from the adult epidemic. There is a striking non-linear relationship 
between decreasing disease prevalence and PPV of the HIV DNA 
PCR tests, as shown from the calculations of HIV DNA PCR testing 
in South Africa that show the rapid decrease in PPV of the test when 
disease prevalence drops below 10%. This means that countries with 
improving PMTCT programmes must revisit testing algorithms, 
as the shifting epidemic itself causes major changes in the PPV of 
the virological assay. Any quality assurance compromise at clinic or 
laboratory level potentially decreases test specificity, further rapidly 
decreasing the PPV of a single positive test. Laboratory accreditation 
and continued quality control are therefore critical. The NPV of the 
test is excellent, meaning that a child without continued exposure 
can safely be labelled as HIV-uninfected with one negative test, even 
within a possible context of compromised laboratory services with 
decreasing test sensitivity.
HIV testing strategies must differentiate whether testing is done in 
children who have clinical signs of HIV disease or in asymptomatic 
children from the PMTCT programme, as testing algorithms must 
take into account the disease prevalence in the tested population.10,15 
The laboratory capacity to do HIV testing on all HIV-exposed 
infants has expanded greatly in countries such as South Africa, 
but is a potential limiting factor.10 Testing algorithms must be 
cost-effective, with incremental costs added with each additional 
step whereas, conversely, insufficient testing may compromise 
individual patient safety.17 The WHO recommends a 3-test strategy 
for asymptomatic people, when the population prevalence is less than 
5%, as in asymptomatic infants tested in well-functioning PMTCT 
programmes.15
The updated SA Paediatric HIV guidelines (2010) recommend 
HIV testing in infants using 1 HIV DNA PCR test, with an HIV RNA 
viral load above 10 000 copies/ml (>log104) used as a confirmatory 
test.16 In our study, 82% of HIV viral loads done on children with 
false-positive HIV DNA PCR results were undetectable, while the 
false-positive detectable viral loads were all below the threshold of 
log104. Training of healthcare workers is paramount to avoid low-level 
positive HIV viral load results being interpreted as proof of the HIV-
positive status of an uninfected child.11
For countries similar to South Africa, with expanding PMTCT 
interventions aimed at reducing the transmission rate to <5% and the 
laboratory capacity to do HIV DNA PCR tests, it is strongly advised to 
move to a 3-test strategy and add a confirmatory HIV DNA PCR test to 
the current testing strategy for asymptomatic infants who have 1 positive 
HIV DNA PCR test. The additional cost of testing will decrease as HIV 
prevalence in children declines and there are fewer positive results owing 
to PMTCT interventions. Also, costs will be recovered by avoiding ART 
initiation in HIV-uninfected children. Clinicians must guard against 
a false sense of security when a test has an excellent specificity as, in a 
setting of low disease prevalence, the PPV of the test is decreased. This is 
especially true in a changing epidemic, when the risk of infection status 
is not constant over time, as is the current situation with the paediatric 
HIV epidemic in sub-Saharan Africa.
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